By reducing hepatic enzyme levels and improving markers of hepatic steatosis or fibrosis, bariatric surgery may help reduce the risk of non-alcoholic fatty liver disease (NAFLD), according to a study from Portugal presented at ENDO 2020.
There is a high incidence of psychiatric comorbidities among gender nonconforming teenagers, with about two-thirds and one-third experiencing depression and anxiety, respectively, according to a study presented at ENDO 2020.
Adding liraglutide to first-line lifestyle therapy led to a significantly reduced BMI standard-deviation score (BMI SDS*) among obese adolescents who failed to respond to lifestyle therapy alone, according to a study presented at ENDO 2020.
The investigational, oral formulation of octreotide appeared to be effective and safe as maintenance treatment for adults with acromegaly, according to the results of the phase III OPTIMAL* study presented at ENDO 2020.
Use of thyroid replacement therapy in older people with isolated elevations in TSH* was associated with a significantly increased risk of death than those who were left untreated, according to the BLSA** study presented at ENDO 2020 — which raises the possibility of overtreatment in these older adults.
The human monoclonal anti-IGF-1R* antibody teprotumumab was effective in reducing proptosis or eye bulging in patients with the rare thyroid eye disease (TED) regardless of age, gender, and/or smoking status, according to pooled data presented at ENDO 2020.
Maintaining a good control of blood glucose level may slow down the decline of cognitive function in patients with type 2 diabetes (T2D) after a lacunar stroke, suggests a post hoc analysis of the SPS3* trial presented at the ENDO 2020 Virtual Meeting.
Interim results of REGENERATE* trial highlight the ability of experimental noninvasive tests to evaluate treatment response in adults with NASH** and advanced liver fibrosis who are receiving obeticholic acid (OCA).
The combination of pitavastatin and fenofibrate appears to have superior effect on non-high-density lipoprotein cholesterol (non–HDL-C), as well as other lipids, compared with a statin alone in high-risk patients with mixed dyslipidemia, according to a study.